Comparative Pharmacology
Head-to-head clinical analysis: DYCILL versus V CILLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCILL versus V CILLIN.
DYCILL vs V-CILLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G benzathine is a slow-release parenteral formulation of penicillin G that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Penicillin G (V-CILLIN) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin activation, leading to cell lysis.
250 mg orally every 6 hours or 500 mg orally every 12 hours.
250-500 mg orally every 8 hours or 500 mg every 12 hours for mild to moderate infections.
None Documented
None Documented
0.5-1 hour; prolonged in renal impairment (up to 20 hours in severe cases).
Terminal elimination half-life ~30-60 minutes in normal renal function; prolonged in renal impairment (up to 10 hours in anuria).
Renal: approx. 60-80% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: minor (less than 10%).
Primarily renal (60-70% unchanged via tubular secretion); minor biliary/fecal elimination (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic